Detalhe da pesquisa
1.
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Mult Scler
; 29(6): 719-730, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012898
2.
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Mult Scler
; 28(4): 608-619, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378456
3.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Mult Scler
; 28(9): 1424-1456, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196927
4.
The Dual Role of the ß2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis.
Int J Mol Sci
; 23(2)2022 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35054851
5.
Muscle Regeneration in Holothurians without the Upregulation of Muscle Genes.
Int J Mol Sci
; 23(24)2022 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36555677
6.
Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?
Int J Mol Sci
; 22(10)2021 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34070011
7.
Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity.
BMC Microbiol
; 19(1): 309, 2019 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31888483
8.
International consensus on quality standards for brain health-focused care in multiple sclerosis.
Mult Scler
; 25(13): 1809-1818, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30381987
9.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med
; 373(15): 1418-28, 2015 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26444729
10.
Pediatric multiple sclerosis: a review.
BMC Neurol
; 18(1): 27, 2018 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523094
11.
New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
Mult Scler
; 23(2_suppl): 155-165, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28643590
12.
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Mult Scler
; 23(6): 818-829, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503905
13.
Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Pharmacogenet Genomics
; 26(3): 103-15, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26678572
14.
The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple Sclerosis.
Neuroimmunomodulation
; 23(4): 217-223, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27710965
15.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
N Engl J Med
; 366(11): 1000-9, 2012 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22417253
16.
Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
Mult Scler
; 26(7): 869-870, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31625816
17.
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Mult Scler
; 21(1): 22-34, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25344374
18.
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Mult Scler
; 21(8): 1025-35, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25432952
19.
Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity.
Int J Mol Sci
; 16(8): 20067-81, 2015 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26305248
20.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Ann Neurol
; 73(6): 705-13, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23686821